<DOC>
	<DOCNO>NCT00450450</DOCNO>
	<brief_summary>This randomized phase III trial study donor bone marrow transplant without G-CSF compare well work treat young patient hematologic cancer disease . Giving chemotherapy total-body irradiation donor bone marrow transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving methotrexate tacrolimus cyclosporine transplant may stop happen . It yet know whether donor bone marrow transplant effective without G-CSF treat hematologic cancer disease .</brief_summary>
	<brief_title>Donor Bone Marrow Transplant With Without G-CSF Treating Young Patients With Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Compare improvement event-free survival patient hematologic cancer diseases undergo filgrastim ( G-CSF ) -stimulated bone marrow transplantation ( BMT ) vs conventional BMT . SECONDARY OBJECTIVES : I . Compare incidence time engraftment patient treat regimen . II . Compare rate acute chronic graft-vs-host disease ( GVHD ) patient treat regimen . III . Correlate incidence acute chronic GVHD absolute T-cell number , Th1 v Th2 profile T cell , dendritic cell population , T-regulatory cell content . IV . Assess impact G-CSF-stimulated BMT stem cell source hospital stay treatment-related mortality day 100 patient treated regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord risk ( high v intermediate v standard ) . CONDITIONING REGIMEN : Co-enrolled COG-ASCT0431 COG-AAML0531 ; Patients receive condition regimen define treatment study . ACUTE LYMPHOBLASTIC LEUKEMIA ( ALL ) : Patients undergo total-body irradiation ( TBI ) twice daily day -8 -6 . Patients receive thiotepa IV day -5 -4 high-dose cyclophosphamide IV 1 hour day -3 -2 . Some patient CNS leukemia high-risk ALL first complete remission receive cranial radiotherapy . ACUTE MYELOID LEUKEMIA , JUVENILE MYELOMONOCYTIC , CHRONIC MYELOGENOUS LEUKEMIA , OR MYELODYSPLASTIC SYNDROMES : ( myeloid malignancy ) Patients receive busulfan IV 2 hour every 6 hour day -9 -6 high-dose cyclophosphamide IV 1 hour day -5 -2 . GRAFT-VS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Co-enrolled COG-ASCT0431 COG-AAML0531 : Patients undergo GVHD prophylaxis define treatment study . ALL : Patients receive tacrolimus IV orally begin day -2 continue day 42 , follow taper day 98 . Patients also receive methotrexate IV day 1 , 3 , 6 . MYELOID MALIGNANCIES : Patients receive cyclosporine IV continuously orally begin day -1 continue day 42 day 50 , follow taper 8-16 week . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . ALLOGENEIC BONE MARROW TRANSPLANTATION ( BMT ) : Patients randomize 1 2 transplantation arm . ARM I : Patients undergo filgrastim ( G-CSF ) -stimulated allogeneic BMT day 0 . ARM II : Patients undergo conventional allogeneic BMT day 0 . After completion study treatment , patient follow 1 year annually 5-10 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis hematologic cancer disease , include follow : Chronic myelogenous leukemia first second chronic phase Acute lymphoblastic leukemia ( ALL ) , meet follow criterion : Relapsed ALL enrol Children 's Oncology Group ( COG ) relapse clinical trial OR receive ≥ 1 round reinduction therapy ( 46 week ) 1 round intensive consolidation chemotherapy ( 36 week ) ALL second complete remission ( CR ) * bone marrow , extramedullary , combine bone marrow extramedullary relapse Very highrisk ALL first CR , define follow : Philadelphia chromosomepositive ALL Hypodiploidy ( &lt; 44 chromosome ) Mixed lineage leukemia rearrangement Induction failure Acute myeloid leukemia first second CR Induction therapy must complete Juvenile myelomonocytic leukemia Myelodysplastic syndromes No clinically evident CNS extramedullary disease No blast see cerebrospinal fluid cytospin Postrelapse reinduction therapy must complete Not plan receive reducedintensity condition regimen Not plan receive graft undergone Tcell depletion No Down syndrome Matched sibling donor must available must enrol ASCT0631D companion study Karnofsky performance status ( PS ) 60100 % ( patient &gt; 16 year age ) OR Lansky PS 60100 % ( patient ≤ 16 year age ) AST ALT &lt; 5 time upper limit normal age Bilirubin &lt; 2.5 mg/dL ( unless due Gilbert 's syndrome ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base age and/or gender follow : 0.4 mg/dL ( 1 month &lt; 6 month age ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( ≥ 16 year age ) Shortening fraction ≥ 27 % echocardiogram OR LVEF ≥ 50 % radionuclide angiogram FEV_1 , FVC , DLCO ≥ 60 % OR meet follow criterion ( patient unable cooperate pulmonary function test ) : No evidence dyspnea rest No exercise intolerance No requirement supplemental oxygen therapy Not pregnant nursing No known HIV No known uncontrolled fungal , bacterial , viral infection Patients acquire fungal disease induction therapy may proceed significant response antifungal therapy minimal evidence disease remain CT scan No prior allogeneic autologous stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>